Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Agree, the directors wouldn’t have committed such a large amount of personal funds if they weren’t confident in their research and what lies ahead. Hopefully now we’re entering a news rich period :)
It's all good and now look forward to a flow if positive news. Gla ;-)
At least we’re back to blue Dave. Now we anxiously await to see who has taken the other shares, TR1 perhaps?
Anyone want own up on the selling front here.
Just ridiculous and what as the point in investing in the first place.
Everything about this company is incredibly positive and it's astonishing that we are so low regarding share price.
Hard to fathom.
Thanks
£715k added to the non dilutive grants. Rare to find a company where the cash exceeds the mcap 👌🏻
No worries will ADD IF SHE DRIFTS IM LONG HERE SO DROPPING TO 1.25 MAKES no difference to me .For me its the end game im interested in .Have a great day all
Tried to buy at 1,5p a few wont let me want 1,58 might have to bite the bullet will try 1.52/4
Not loads but enough for a trade . Seems a decent price but who knows . GLA DIDNT THINK i see under 130 buy op again . Oil is i think 87 talk of going to 100
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,558 followers
7h
The first #NASH treatment is FDA approved! Despite its growing rates, the disease went largely understudied for decades - until now. Genflow Biosciences (LON:GENF) (OTCQB:GENFF) and its peers are developing life saving medicine to change the lives of millions.
Read more: htTps://loom.ly/fYAsZzA
Healthy Returns: The first drug for a common, deadly liver disease is here – and more are coming
PUBLISHED TUE, MAR 19 2024
In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals' drug "Rezdiffra," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.
The agency's approval is also a big deal because it means Madrigal has succeeded in an area where several other drugmakers have failed – or are still trying to crack.
That gives Madrigal an edge in a market that could be huge: The MASH industry could be worth nearly $26 billion by 2032 across the U.S., France, Germany, Italy, Spain, the U.K. and Japan, according to an estimate from data analytics firm GlobalData.
Madrigal's drug is setting the bar for efficacy and safety for MASH treatment, while also opening the door for medicines still in development.
There's one important detail in the approval that could bode well for the entire MASH space: The FDA isn't requiring patients to get a liver biopsy to determine their eligibility for Madrigal's drug.
That refers to a procedure in which a doctor removes a small piece of liver tissue from a patient so they can examine it under a microscope for signs of damage or disease.
"The absence of liver biopsy requirement in Rezdiffra's label should buoy biotech stocks" of companies developing MASH treatments and "potentially accelerate and broaden patient access," William Blair analyst Andy Hsieh wrote in a note on Friday.
htTps://www.cnbc.com/2024/03/19/healthy-returns-first-nash-liver-disease-drug-is-here-more-coming.html
March 2024 Company Presentation
hTtps://genflowbio.com/wp-content/uploads/2024/03/GenflowBio_Presentation_3-6-24.pdf
That's my plan......On and UP!!! Gla ;-)
That’s it, hold for gold
Kind thanks Northeast14 as you all know with pharma takes time .Not all get there but geneflow has great potential . Where is the bottom who knows . BUT I SUSPECT at these prices we are not far out . No need to keep looking every five mins here as i understand the path ahead here . Good luck all
Money,
The word is the institution are definitely coming! The only way is up.
GLA
Lol, you've got a few more than me Northeast, but i'll be closing the gap tomorrow if all goes to plan. The current rockbottom low sp could be the bargain of the century in the not too distant , with multiple potential opportunities /scenarios to propel Genflow’s value skywards. Gl :-)
Money!
You will be at TR1 soon. Leave some cheap tickets for us please.
Good to see some strong hands entering. There is a telegram group too if anyone wants to join. If you look up #genf on twitter you may be able to find the link as it gets censored here 👌🏻
Plenty of buying today Northeast, but hopefully no news just yet as I'm planning to buy a few myself tomorrow, with funds incoming. Gl :-)
Welcome Score!
I have it at roughly 2.5m if buys today. Most showing as sells. Somethings happening maybe another TR1 will show soon.
1500 could turn into a lot of money in 2 years will take a stake to start
Yes indeed Northeast, no doubt Madrigal will want to protect/dominate the Nash space by acquisition , as well as other Major's currently involved in Nash R & D...... Exciting times ahead. Gl ;-)
Money,
My thoughts on this when I read they may look at acquisitions. Genflow will 100% get looked at here. Especially after that paper being released last week re patent! They have everything that big pharma’s need. We have the R&D and the patents to back it. Fantastic!
Other biopharma players including Pfizer, Bristol Myers Squibb and Genfit have all tried to get into the NASH field as well. Madrigal’s offering, meanwhile, was the first to meet the goals of both MASH resolution and fibrosis improvement in a phase 3 study.
The company is pricing Rezdiffra at a wholesale acquisition cost of $47,400 before discounts. Analysts at Evercore ISI have previously pegged peak global sales at $5.5 billion, and the analyst team expects the drug to generate about $2.6 billion in 2030.
Crucially, the FDA’s approval comes without the requirement of a liver biopsy to determine patient eligibility. That was a major point of contention among investors ahead of the approval, as the invasive procedure would have constrained wide access to the med.
hTtps://www.fiercepharma.com/pharma/after-monumental-mash-nod-its-rezdiffra-madrigal-plots-600m-stock-sale-support-upcoming
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,546 followers
3d
Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is glad to see the mounting interest in Nonalcoholic Steatohepatitis (NASH). The field was notably understudied until recently, when Genflow Biosciences and fellow pioneers began developing promising new treatments revolving around #SIRT6.
Our CEO, Dr Eric Leire, points to a recent EMBO Press report as an example of the growing attention, which also lends support to our research in #NASH.
Read the report here: hTtps://loom.ly/Z_O_-tE